FRANKLIN LAKES, N.J., Feb. 15, 2023 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced that the company has been named to America’s Best Large Employers List 2023 by Forbes, furthering its progress against the company’s environmental, social and governance (ESG) strategy. “This recognition is a reflection […]
Financial
Anteris Announces Completion of A$35 Million Capital Raise and Provides 2023 Goalposts
Company Funded Through Results of U.S. Early Feasibility Study of DurAVR™ BRISBANE, Australia and EAGAN, Minn.–(BUSINESS WIRE)–Anteris Technologies Ltd (ASX: AVR), a structural heart company developing DurAVR™, the world’s only balloon-expandable, 3D single-piece biomimetic aortic valve, announced today the completion of a A$35M equity fundraising initiated on February 9th 2023. In […]
InspireMD Announces Hiring of Medical Device Commercial Veteran Shane Gleason as General Manager of North America and VP of Global Marketing
Seasoned veteran in vascular space adds significant expertise in U.S. commercial market readiness and global strategic marketing TEL AVIV, Israel, Feb. 14, 2023 (GLOBE NEWSWIRE) — InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced that it has hired […]
Cardiac AI-Pioneer Cleerly Partners with ClearDATA to Protect Patient Data
Cleerly revolutionizes precision healthcare by leveraging secure patient imaging for AI interpretation AUSTIN, Texas, Feb. 14, 2023 (GLOBE NEWSWIRE) — ClearDATA®, healthcare’s most comprehensive managed cloud, compliance and cyber defense provider, today announced a partnership with Cleerly, the company leveraging artificial intelligence (AI) to forge a new standard of prevention and care […]
Curi Bio Names Nicholas A. Geisse, Ph.D., as New Chief Executive Officer
Dr. Geisse brings 15 years of life science experience after having led scientific strategy for Curi Bio since 2017. SEATTLE–(BUSINESS WIRE)–Curi Bio, a leading developer of human stem cell-based platforms for drug discovery, today announced the appointment of Nicholas A. Geisse, Ph.D. as Chief Executive Officer, effective immediately. Dr. Geisse […]
ABBOTT TO ACQUIRE CARDIOVASCULAR SYSTEMS, INC.
Abbott will gain an innovative, complementary solution in treating vascular disease through CSI’s leading atherectomy system, which prepares vessels for angioplasty or stenting to restore blood flow CSI’s offering will support Abbott’s ability to provide better care for patients with peripheral and coronary artery disease ABBOTT PARK, Ill. and ST. PAUL, […]
AbbVie Reports Full-Year and Fourth-Quarter 2022 Financial Results
Reports Full-Year Diluted EPS of $6.63 on a GAAP Basis, an Increase of 2.8 Percent; Adjusted Diluted EPS of $13.77, an Increase of 16.4 Percent; These Results Include an Unfavorable Impact of $0.39 Per Share related to 2022 Acquired IPR&D and Milestones Expense1 Delivers Full-Year Net Revenues of $58.054 Billion, an Increase of 3.3 Percent on […]
TIOGA CARDIOVASCULAR, A SHIFAMED PORTFOLIO COMPANY, CLOSES $30M IN SERIES C FINANCING
Funding to advance product development and initiate clinical experience of company’s next-generation technology for transseptal mitral valve replacement LOS GATOS, Calif., Feb. 9, 2023 /PRNewswire/ — Tioga Cardiovascular, a Shifamed portfolio company that aims to redefine structural heart valve replacement, announced today the first closing of its $30M Series C financing. Led by Cormorant Asset Management, […]
Cardiovascular Systems, Inc. Reports Fiscal 2023 Second Quarter Financial Results
ST. PAUL, Minn.–(BUSINESS WIRE)–Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today reported financial results for its second quarter, ended December 31, 2022. Second Quarter Financial Highlights CSI’s fiscal 2023 second quarter revenues […]
Baxter Reports Fourth-Quarter and Full-Year 2022 Results
Fourth-quarter sales of $3.9 billion increased 11% on a reported basis, 17% on a constant currency basis and 2% on an operational basis1 Fourth-quarter U.S. GAAP diluted earnings per share (EPS) of $0.36 and adjusted diluted EPS of $0.88 Full-year sales of $15.1 billion increased 18% on a reported basis, […]



